[{"edinetCode":"E05363","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":54.0,"averageTemporaryStaff":9.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":39273700.0,"sharesOwendPercent":0.2671,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":65.97,"equityRatio":0.916,"cashAndCashEquivalents":10072962000.0,"assets":10592771000.0,"currentAssets":10288900000.0,"fixedAsset":303871000.0,"tangibleFixedAssets":219804000.0,"intangibleFixedAssets":15926000.0,"investmentAndOtherAssets":68140000.0,"liabilities":488473000.0,"currentLiabilities":369909000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":118564000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":10104297000.0,"capitalStock":9707069000.0,"capital":9135118000.0,"capitalSurplus":12100340000.0,"accumulatedEarnings":-11528389000.0,"treasuryStock":null,"valuationAndConversionAdjustments":-8235000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":352739000.0,"salaryAndBenefit":null,"depreciationAndSGA":10055000.0,"RDExpenses":2938150000.0,"operatingIncome":-3004222000.0,"nonOperatingIncome":1838000.0,"nonOperatingExpenses":6281000.0,"interestExpense":null,"ordinaryProfit":-3008665000.0,"extraordinaryGain":11093000.0,"extraordinaryLoss":null,"incomeBeforeTax":-2997571000.0,"incomeTaxes":4492000.0,"netIncome":-3002063000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-3002063000.0,"comprehensiveIncome":-3001558000.0,"eps":-20.42,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-2988040000.0,"depreciationAndCashflowFromOperatingActivities":89653000.0,"cashFlowFromInvestingActivities":-11958000.0,"cashFlowFromFinancialActivities":2330000.0,"changesInCashAndCashEquivalents":-2997331000.0,"列1":"asr","submitDate":"2017\/6\/20","stockCode":4564,"accountingYear":"第16期（自　平成28年４月１日　至　平成29年３月31日）","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E05363","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50,"settlementDate":"2022\/3\/31","submitterName":"オンコセラピー・サイエンス株式会社","submitterNameEnglish":"OncoTherapy Science, Inc.","submitterNameKana":"オンコセラピーサイエンスカブシキガイシャ","location":"川崎市高津区坂戸三丁目２番１号","industory":"医薬品","corporateNumber":1020000000000.0},{"edinetCode":"E05363","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":56.0,"averageTemporaryStaff":8.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":37540047.0,"sharesOwendPercent":0.2553,"outstandingShares":null,"numberOfSubsidiary":3.0,"bps":47.44,"equityRatio":0.87,"cashAndCashEquivalents":6740238000.0,"assets":8021524000.0,"currentAssets":7034066000.0,"fixedAsset":987458000.0,"tangibleFixedAssets":581970000.0,"intangibleFixedAssets":284938000.0,"investmentAndOtherAssets":120548000.0,"liabilities":441685000.0,"currentLiabilities":306135000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":135549000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":7579839000.0,"capitalStock":6984958000.0,"capital":50455000.0,"capitalSurplus":21313985000.0,"accumulatedEarnings":-14379482000.0,"treasuryStock":null,"valuationAndConversionAdjustments":-9250000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":211251000.0,"costOfSales":null,"grossProfit":null,"sgaExpenses":267945000.0,"salaryAndBenefit":null,"depreciationAndSGA":7635000.0,"RDExpenses":2931901000.0,"operatingIncome":-2988595000.0,"nonOperatingIncome":11442000.0,"nonOperatingExpenses":24000.0,"interestExpense":null,"ordinaryProfit":-2977177000.0,"extraordinaryGain":57914000.0,"extraordinaryLoss":null,"incomeBeforeTax":-2919262000.0,"incomeTaxes":6905000.0,"netIncome":-2926168000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-2851092000.0,"comprehensiveIncome":-2927183000.0,"eps":-19.39,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-3035947000.0,"depreciationAndCashflowFromOperatingActivities":148657000.0,"cashFlowFromInvestingActivities":-446421000.0,"cashFlowFromFinancialActivities":150640000.0,"changesInCashAndCashEquivalents":-3332724000.0,"列1":"asr","submitDate":"2018\/6\/22","stockCode":4564,"accountingYear":"第17期（自　平成29年４月１日　至　平成30年３月31日）","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E05363","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50,"settlementDate":"2022\/3\/31","submitterName":"オンコセラピー・サイエンス株式会社","submitterNameEnglish":"OncoTherapy Science, Inc.","submitterNameKana":"オンコセラピーサイエンスカブシキガイシャ","location":"川崎市高津区坂戸三丁目２番１号","industory":"医薬品","corporateNumber":1020000000000.0},{"edinetCode":"E05363","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":63.0,"averageTemporaryStaff":10.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":39448516.0,"sharesOwendPercent":0.2603,"outstandingShares":null,"numberOfSubsidiary":3.0,"bps":30.32,"equityRatio":0.856,"cashAndCashEquivalents":4857670000.0,"assets":5367176000.0,"currentAssets":5055405000.0,"fixedAsset":311771000.0,"tangibleFixedAssets":200777000.0,"intangibleFixedAssets":9377000.0,"investmentAndOtherAssets":101616000.0,"liabilities":496870000.0,"currentLiabilities":367744000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":129126000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":4870306000.0,"capitalStock":4605811000.0,"capital":328362000.0,"capitalSurplus":21591892000.0,"accumulatedEarnings":-17314443000.0,"treasuryStock":null,"valuationAndConversionAdjustments":-10056000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":280586000.0,"costOfSales":null,"grossProfit":null,"sgaExpenses":407723000.0,"salaryAndBenefit":null,"depreciationAndSGA":4263000.0,"RDExpenses":2826639000.0,"operatingIncome":-2953776000.0,"nonOperatingIncome":932000.0,"nonOperatingExpenses":6188000.0,"interestExpense":null,"ordinaryProfit":-2959032000.0,"extraordinaryGain":82883000.0,"extraordinaryLoss":318507000.0,"incomeBeforeTax":-3194655000.0,"incomeTaxes":-2841000.0,"netIncome":-3191814000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-2934960000.0,"comprehensiveIncome":-3192620000.0,"eps":-19.9,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-2373427000.0,"depreciationAndCashflowFromOperatingActivities":391998000.0,"cashFlowFromInvestingActivities":-74207000.0,"cashFlowFromFinancialActivities":565971000.0,"changesInCashAndCashEquivalents":-1882567000.0,"列1":"asr","submitDate":"2019\/6\/20","stockCode":4564,"accountingYear":"第18期（自　2018年４月１日　至　2019年３月31日）","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E05363","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50,"settlementDate":"2022\/3\/31","submitterName":"オンコセラピー・サイエンス株式会社","submitterNameEnglish":"OncoTherapy Science, Inc.","submitterNameKana":"オンコセラピーサイエンスカブシキガイシャ","location":"川崎市高津区坂戸三丁目２番１号","industory":"医薬品","corporateNumber":1020000000000.0},{"edinetCode":"E05363","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.888,"cashAndCashEquivalents":null,"assets":5150743000.0,"currentAssets":4909973000.0,"fixedAsset":240769000.0,"tangibleFixedAssets":140000000.0,"intangibleFixedAssets":8366000.0,"investmentAndOtherAssets":92403000.0,"liabilities":386729000.0,"currentLiabilities":257412000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":129316000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":4764014000.0,"capitalStock":4585338000.0,"capital":640911000.0,"capitalSurplus":21904441000.0,"accumulatedEarnings":-17960013000.0,"treasuryStock":null,"valuationAndConversionAdjustments":-10555000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":55826000.0,"costOfSales":104078000.0,"grossProfit":null,"sgaExpenses":105801000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":463777000.0,"operatingIncome":-617830000.0,"nonOperatingIncome":3448000.0,"nonOperatingExpenses":1766000.0,"interestExpense":null,"ordinaryProfit":-616148000.0,"extraordinaryGain":133176000.0,"extraordinaryLoss":162168000.0,"incomeBeforeTax":-645140000.0,"incomeTaxes":429000.0,"netIncome":-645570000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-645570000.0,"comprehensiveIncome":-646069000.0,"eps":-4.18,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/8\/13","stockCode":4564,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E05363","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50,"settlementDate":"2022\/3\/31","submitterName":"オンコセラピー・サイエンス株式会社","submitterNameEnglish":"OncoTherapy Science, Inc.","submitterNameKana":"オンコセラピーサイエンスカブシキガイシャ","location":"川崎市高津区坂戸三丁目２番１号","industory":"医薬品","corporateNumber":1020000000000.0},{"edinetCode":"E05363","endDate":"2019\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":42126248.0,"sharesOwendPercent":0.2614,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.881,"cashAndCashEquivalents":4530387000.0,"assets":4921751000.0,"currentAssets":4692086000.0,"fixedAsset":229665000.0,"tangibleFixedAssets":132134000.0,"intangibleFixedAssets":6201000.0,"investmentAndOtherAssets":91329000.0,"liabilities":399949000.0,"currentLiabilities":270441000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":129507000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":4521802000.0,"capitalStock":4337263000.0,"capital":822544000.0,"capitalSurplus":22086074000.0,"accumulatedEarnings":-18571355000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":104511000.0,"costOfSales":190377000.0,"grossProfit":null,"sgaExpenses":211241000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":921557000.0,"operatingIncome":-1218664000.0,"nonOperatingIncome":4103000.0,"nonOperatingExpenses":4094000.0,"interestExpense":null,"ordinaryProfit":-1218655000.0,"extraordinaryGain":136330000.0,"extraordinaryLoss":173727000.0,"incomeBeforeTax":-1256052000.0,"incomeTaxes":859000.0,"netIncome":-1256912000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-1256912000.0,"comprehensiveIncome":-1246855000.0,"eps":-8.01,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-1281988000.0,"depreciationAndCashflowFromOperatingActivities":20692000.0,"cashFlowFromInvestingActivities":-24035000.0,"cashFlowFromFinancialActivities":980322000.0,"changesInCashAndCashEquivalents":-327283000.0,"列1":"q2r","submitDate":"2019\/11\/11","stockCode":4564,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E05363","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50,"settlementDate":"2022\/3\/31","submitterName":"オンコセラピー・サイエンス株式会社","submitterNameEnglish":"OncoTherapy Science, Inc.","submitterNameKana":"オンコセラピーサイエンスカブシキガイシャ","location":"川崎市高津区坂戸三丁目２番１号","industory":"医薬品","corporateNumber":1020000000000.0},{"edinetCode":"E05363","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.881,"cashAndCashEquivalents":null,"assets":4866057000.0,"currentAssets":4637928000.0,"fixedAsset":228129000.0,"tangibleFixedAssets":131183000.0,"intangibleFixedAssets":5826000.0,"investmentAndOtherAssets":91118000.0,"liabilities":397663000.0,"currentLiabilities":267964000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":129698000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":4468394000.0,"capitalStock":4287544000.0,"capital":1057147000.0,"capitalSurplus":22320677000.0,"accumulatedEarnings":-19090280000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":161584000.0,"costOfSales":277293000.0,"grossProfit":null,"sgaExpenses":307418000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":1312097000.0,"operatingIncome":-1735225000.0,"nonOperatingIncome":2300000.0,"nonOperatingExpenses":5575000.0,"interestExpense":null,"ordinaryProfit":-1738499000.0,"extraordinaryGain":137679000.0,"extraordinaryLoss":173727000.0,"incomeBeforeTax":-1774548000.0,"incomeTaxes":1289000.0,"netIncome":-1775837000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-1775837000.0,"comprehensiveIncome":-1765781000.0,"eps":-11.16,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/2\/10","stockCode":4564,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E05363","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50,"settlementDate":"2022\/3\/31","submitterName":"オンコセラピー・サイエンス株式会社","submitterNameEnglish":"OncoTherapy Science, Inc.","submitterNameKana":"オンコセラピーサイエンスカブシキガイシャ","location":"川崎市高津区坂戸三丁目２番１号","industory":"医薬品","corporateNumber":1020000000000.0},{"edinetCode":"E05363","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":62.0,"averageTemporaryStaff":9.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":42225400.0,"sharesOwendPercent":0.2395,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":25.81,"equityRatio":0.895,"cashAndCashEquivalents":4713947000.0,"assets":5088076000.0,"currentAssets":4878005000.0,"fixedAsset":210071000.0,"tangibleFixedAssets":113476000.0,"intangibleFixedAssets":6122000.0,"investmentAndOtherAssets":90472000.0,"liabilities":359595000.0,"currentLiabilities":242885000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":116710000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":4728481000.0,"capitalStock":4551502000.0,"capital":1420486000.0,"capitalSurplus":22684016000.0,"accumulatedEarnings":-19553001000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":316215000.0,"costOfSales":366331000.0,"grossProfit":null,"sgaExpenses":397379000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":1742168000.0,"operatingIncome":-2189664000.0,"nonOperatingIncome":2472000.0,"nonOperatingExpenses":10001000.0,"interestExpense":null,"ordinaryProfit":-2197193000.0,"extraordinaryGain":137679000.0,"extraordinaryLoss":177483000.0,"incomeBeforeTax":-2236997000.0,"incomeTaxes":1560000.0,"netIncome":-2238558000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-2238558000.0,"comprehensiveIncome":-2228502000.0,"eps":-13.73,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-2275529000.0,"depreciationAndCashflowFromOperatingActivities":39745000.0,"cashFlowFromInvestingActivities":-30700000.0,"cashFlowFromFinancialActivities":2164089000.0,"changesInCashAndCashEquivalents":-143723000.0,"列1":"asr","submitDate":"2020\/6\/24","stockCode":4564,"accountingYear":"第19期（自　2019年４月１日　至　2020年３月31日）","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E05363","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50,"settlementDate":"2022\/3\/31","submitterName":"オンコセラピー・サイエンス株式会社","submitterNameEnglish":"OncoTherapy Science, Inc.","submitterNameKana":"オンコセラピーサイエンスカブシキガイシャ","location":"川崎市高津区坂戸三丁目２番１号","industory":"医薬品","corporateNumber":1020000000000.0},{"edinetCode":"E05363","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.924,"cashAndCashEquivalents":null,"assets":4578915000.0,"currentAssets":4379597000.0,"fixedAsset":199317000.0,"tangibleFixedAssets":103156000.0,"intangibleFixedAssets":5755000.0,"investmentAndOtherAssets":90405000.0,"liabilities":259430000.0,"currentLiabilities":162912000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":96517000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":4319484000.0,"capitalStock":4232527000.0,"capital":1420486000.0,"capitalSurplus":22684016000.0,"accumulatedEarnings":-19871975000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":41012000.0,"costOfSales":74138000.0,"grossProfit":null,"sgaExpenses":74815000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":291149000.0,"operatingIncome":-399092000.0,"nonOperatingIncome":450000.0,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":-398642000.0,"extraordinaryGain":90022000.0,"extraordinaryLoss":9740000.0,"incomeBeforeTax":-318359000.0,"incomeTaxes":614000.0,"netIncome":-318974000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-318974000.0,"comprehensiveIncome":-318974000.0,"eps":-1.81,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/8\/11","stockCode":4564,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E05363","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50,"settlementDate":"2022\/3\/31","submitterName":"オンコセラピー・サイエンス株式会社","submitterNameEnglish":"OncoTherapy Science, Inc.","submitterNameKana":"オンコセラピーサイエンスカブシキガイシャ","location":"川崎市高津区坂戸三丁目２番１号","industory":"医薬品","corporateNumber":1020000000000.0},{"edinetCode":"E05363","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":40139736.0,"sharesOwendPercent":0.2276,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.914,"cashAndCashEquivalents":3729748000.0,"assets":4152746000.0,"currentAssets":3964691000.0,"fixedAsset":188054000.0,"tangibleFixedAssets":92329000.0,"intangibleFixedAssets":5386000.0,"investmentAndOtherAssets":90338000.0,"liabilities":270955000.0,"currentLiabilities":174265000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":96689000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":3881790000.0,"capitalStock":3794834000.0,"capital":50000000.0,"capitalSurplus":24054503000.0,"accumulatedEarnings":-20309669000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":100828000.0,"costOfSales":152269000.0,"grossProfit":null,"sgaExpenses":145329000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":641821000.0,"operatingIncome":-838592000.0,"nonOperatingIncome":2712000.0,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":-835879000.0,"extraordinaryGain":90022000.0,"extraordinaryLoss":9740000.0,"incomeBeforeTax":-755597000.0,"incomeTaxes":1070000.0,"netIncome":-756667000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-756667000.0,"comprehensiveIncome":-756667000.0,"eps":-4.29,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-968543000.0,"depreciationAndCashflowFromOperatingActivities":26572000.0,"cashFlowFromInvestingActivities":-15656000.0,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":-984199000.0,"列1":"q2r","submitDate":"2020\/11\/9","stockCode":4564,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E05363","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50,"settlementDate":"2022\/3\/31","submitterName":"オンコセラピー・サイエンス株式会社","submitterNameEnglish":"OncoTherapy Science, Inc.","submitterNameKana":"オンコセラピーサイエンスカブシキガイシャ","location":"川崎市高津区坂戸三丁目２番１号","industory":"医薬品","corporateNumber":1020000000000.0},{"edinetCode":"E05363","endDate":"2020\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.903,"cashAndCashEquivalents":null,"assets":3729614000.0,"currentAssets":3537721000.0,"fixedAsset":191892000.0,"tangibleFixedAssets":96462000.0,"intangibleFixedAssets":5158000.0,"investmentAndOtherAssets":90272000.0,"liabilities":273931000.0,"currentLiabilities":177671000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":96260000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":3455682000.0,"capitalStock":3368725000.0,"capital":50000000.0,"capitalSurplus":24054503000.0,"accumulatedEarnings":-20735778000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":160113000.0,"costOfSales":234912000.0,"grossProfit":null,"sgaExpenses":218895000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":972539000.0,"operatingIncome":-1266234000.0,"nonOperatingIncome":4450000.0,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":-1261784000.0,"extraordinaryGain":90022000.0,"extraordinaryLoss":9878000.0,"incomeBeforeTax":-1181640000.0,"incomeTaxes":1136000.0,"netIncome":-1182776000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-1182776000.0,"comprehensiveIncome":-1182776000.0,"eps":-6.71,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/2\/8","stockCode":4564,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E05363","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50,"settlementDate":"2022\/3\/31","submitterName":"オンコセラピー・サイエンス株式会社","submitterNameEnglish":"OncoTherapy Science, Inc.","submitterNameKana":"オンコセラピーサイエンスカブシキガイシャ","location":"川崎市高津区坂戸三丁目２番１号","industory":"医薬品","corporateNumber":1020000000000.0},{"edinetCode":"E05363","endDate":"2021\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":66.0,"averageTemporaryStaff":5.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":38133238.0,"sharesOwendPercent":0.2165,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":16.96,"equityRatio":0.888,"cashAndCashEquivalents":2899092000.0,"assets":3368102000.0,"currentAssets":3194105000.0,"fixedAsset":173996000.0,"tangibleFixedAssets":94936000.0,"intangibleFixedAssets":4724000.0,"investmentAndOtherAssets":74335000.0,"liabilities":291279000.0,"currentLiabilities":194921000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":96358000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":3076822000.0,"capitalStock":2989865000.0,"capital":50000000.0,"capitalSurplus":24054503000.0,"accumulatedEarnings":-21114637000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":332477000.0,"costOfSales":312935000.0,"grossProfit":null,"sgaExpenses":281795000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":1375683000.0,"operatingIncome":-1637936000.0,"nonOperatingIncome":2385000.0,"nonOperatingExpenses":3711000.0,"interestExpense":null,"ordinaryProfit":-1639262000.0,"extraordinaryGain":90071000.0,"extraordinaryLoss":10821000.0,"incomeBeforeTax":-1560012000.0,"incomeTaxes":1623000.0,"netIncome":-1561636000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-1561636000.0,"comprehensiveIncome":-1561636000.0,"eps":-8.86,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-1762629000.0,"depreciationAndCashflowFromOperatingActivities":49008000.0,"cashFlowFromInvestingActivities":-52225000.0,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":-1814854000.0,"列1":"asr","submitDate":"2021\/6\/22","stockCode":4564,"accountingYear":"第20期（自　2020年４月１日　至　2021年３月31日）","accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E05363","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50,"settlementDate":"2022\/3\/31","submitterName":"オンコセラピー・サイエンス株式会社","submitterNameEnglish":"OncoTherapy Science, Inc.","submitterNameKana":"オンコセラピーサイエンスカブシキガイシャ","location":"川崎市高津区坂戸三丁目２番１号","industory":"医薬品","corporateNumber":1020000000000.0},{"edinetCode":"E05363","endDate":"2021\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.876,"cashAndCashEquivalents":null,"assets":3595376000.0,"currentAssets":3426528000.0,"fixedAsset":168847000.0,"tangibleFixedAssets":90145000.0,"intangibleFixedAssets":4366000.0,"investmentAndOtherAssets":74335000.0,"liabilities":394398000.0,"currentLiabilities":307412000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":86985000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":3200978000.0,"capitalStock":3149637000.0,"capital":397350000.0,"capitalSurplus":24401854000.0,"accumulatedEarnings":-21649566000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":93183000.0,"costOfSales":76686000.0,"grossProfit":null,"sgaExpenses":120170000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":467843000.0,"operatingIncome":-571517000.0,"nonOperatingIncome":452000.0,"nonOperatingExpenses":444000.0,"interestExpense":null,"ordinaryProfit":-571509000.0,"extraordinaryGain":47902000.0,"extraordinaryLoss":11036000.0,"incomeBeforeTax":-534644000.0,"incomeTaxes":284000.0,"netIncome":-534929000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-534929000.0,"comprehensiveIncome":-534929000.0,"eps":-3.0,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/8\/10","stockCode":4564,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E05363","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50,"settlementDate":"2022\/3\/31","submitterName":"オンコセラピー・サイエンス株式会社","submitterNameEnglish":"OncoTherapy Science, Inc.","submitterNameKana":"オンコセラピーサイエンスカブシキガイシャ","location":"川崎市高津区坂戸三丁目２番１号","industory":"医薬品","corporateNumber":1020000000000.0},{"edinetCode":"E05363","endDate":"2021\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":40463224.0,"sharesOwendPercent":0.2129,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.812,"cashAndCashEquivalents":3122986000.0,"assets":3738201000.0,"currentAssets":3564005000.0,"fixedAsset":174196000.0,"tangibleFixedAssets":85541000.0,"intangibleFixedAssets":4023000.0,"investmentAndOtherAssets":84630000.0,"liabilities":639219000.0,"currentLiabilities":541898000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":97321000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":3098981000.0,"capitalStock":3037101000.0,"capital":688482000.0,"capitalSurplus":24692985000.0,"accumulatedEarnings":-22344366000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":240607000.0,"costOfSales":218896000.0,"grossProfit":null,"sgaExpenses":222660000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":747814000.0,"operatingIncome":-948764000.0,"nonOperatingIncome":509000.0,"nonOperatingExpenses":3791000.0,"interestExpense":null,"ordinaryProfit":-952046000.0,"extraordinaryGain":47902000.0,"extraordinaryLoss":324781000.0,"incomeBeforeTax":-1228924000.0,"incomeTaxes":803000.0,"netIncome":-1229728000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-1229728000.0,"comprehensiveIncome":-1229728000.0,"eps":-6.74,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-1033067000.0,"depreciationAndCashflowFromOperatingActivities":11047000.0,"cashFlowFromInvestingActivities":-24811000.0,"cashFlowFromFinancialActivities":1281772000.0,"changesInCashAndCashEquivalents":223893000.0,"列1":"q2r","submitDate":"2021\/11\/8","stockCode":4564,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E05363","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50,"settlementDate":"2022\/3\/31","submitterName":"オンコセラピー・サイエンス株式会社","submitterNameEnglish":"OncoTherapy Science, Inc.","submitterNameKana":"オンコセラピーサイエンスカブシキガイシャ","location":"川崎市高津区坂戸三丁目２番１号","industory":"医薬品","corporateNumber":1020000000000.0},{"edinetCode":"E05363","endDate":"2021\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.805,"cashAndCashEquivalents":null,"assets":2892205000.0,"currentAssets":2723529000.0,"fixedAsset":168675000.0,"tangibleFixedAssets":80359000.0,"intangibleFixedAssets":3685000.0,"investmentAndOtherAssets":84630000.0,"liabilities":490961000.0,"currentLiabilities":390414000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":100546000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":2401243000.0,"capitalStock":2328883000.0,"capital":789114000.0,"capitalSurplus":24793617000.0,"accumulatedEarnings":-23253848000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":335214000.0,"costOfSales":336039000.0,"grossProfit":null,"sgaExpenses":328805000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":1380684000.0,"operatingIncome":-1710315000.0,"nonOperatingIncome":819000.0,"nonOperatingExpenses":12215000.0,"interestExpense":null,"ordinaryProfit":-1721711000.0,"extraordinaryGain":49250000.0,"extraordinaryLoss":465428000.0,"incomeBeforeTax":-2137889000.0,"incomeTaxes":1321000.0,"netIncome":-2139211000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-2139211000.0,"comprehensiveIncome":-2139211000.0,"eps":-11.52,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2022\/2\/7","stockCode":4564,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E05363","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50,"settlementDate":"2022\/3\/31","submitterName":"オンコセラピー・サイエンス株式会社","submitterNameEnglish":"OncoTherapy Science, Inc.","submitterNameKana":"オンコセラピーサイエンスカブシキガイシャ","location":"川崎市高津区坂戸三丁目２番１号","industory":"医薬品","corporateNumber":1020000000000.0}]